< >

LeterMovir

Letomovir is a new drug developed with the aid of Merck Pharmaceuticals for the therapy of grownup sufferers with nice cytomegalovirus (CMV) serum after allogeneic hematopoietic stem mobile transplantation (HSCT). It was once authorized with the aid of the US FDA on November 9, 2017 and is marketed underneath the change title Prevymis. Letermovir (AIC246, MK-8228) is a novel anti CMV compound that aims viral terminal enzyme complexes and is additionally lively in viruses that are resistant to DNA polymerase inhibitors.

Contact Now E-Mail Telephone WhatsApp

Product Details

name	LeterMovir
CAS NO	917389-32-3
Molecular formula	C29H28F4N4O4
molecular weight	572.55
boiling point	706.5±70.0 °C(Predicted)
density	1.37±0.1 g/cm3(Predicted)
Storage conditions	Sealed in dry,Store in freezer, under -20°C
solubility	≥57.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form	solid